前列腺癌患者雄激素剥夺治疗后的代谢营养问题

doi:10.16689/j.cnki.cn11-9349/r.2020.02.019

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (998 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Prostate cancer is among one of the most common malignant tumors in men， and androgen deprivation therapy is the first-line treatment for prostate cancer. Prolonged androgen deprivation therapy for patients with prostate cancer who continues to be in a state of low androgen will have a series of metabolic and nutritional problems， including increased risk of obesity， diabetes， abnormal fat metabolism， metabolic syndrome， and cardiovascular disease， etc. The adverse health effect has a negative influence on patient’s quality of life， the implementation of cancer sequential treatments， and the prognosis. However， there are few relevant researches in this field. This article focuses on the metabolism and nutritional issues of prolonged androgen deprivation therapy for prostate cancer patients， discusses in-depth on the obesity， diabetes， dyslipidemia， and metabolic syndrome， and prospects for future research.

Key words： Prostate cancer Androgen deprivation therapy Metabolism Nutrition

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Cai Jianliang1
	Dong Guang2
	Shi Hanping3

Cite this article:

Cai Jianliang1,Dong Guang2,Shi Hanping3. Review on metabolism and nutrition after androgen deprivation therapy in prostate cancer patients[J]. Electron J Metab Nutr Cancer, 2020, 7(2): 236-239.

URL:

http://182.92.200.144/EN/10.16689/j.cnki.cn11-9349/r.2020.02.019 OR http://182.92.200.144/EN/Y2020/V7/I2/236

1.SIEGEL R L， MILLER K D， JEMAL A. Cancer statistics， 2019［J］. CA Cancer J Clin， 2019， 69（1）: 7-34.
2.MOHLER J L， ANTONARAKIS E S， ARMSTRONG A J， et al. NCCN guidelines on prostate cancer［R/OL］. （2020-03-16）［2019-04-17］. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
3.MOTTET N， CORNFORD P， van den BERGH R C N， et al. EAU guidelines on prostate cancer 2019［R/OL］. （ 2020-03-25）［2019-04-17］. https://uroweb.org/guideline/prostate-cancer/#6_4.
4.那彦群，孙颖浩.前列腺癌诊断治疗指南［M］//那彦群，叶章群，孙颖浩，等.中国泌尿外科疾病诊断治疗指南: 2014版.北京: 人民卫生出版社， 2013: 61-89.
5.NABID A， CARRIER N， MARTIN A G， et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase Ⅲ trial［J］. Eur Urol， 2018， 74（4）: 432-441.
6.BOEV L M S， HULSHOF M C C M， VIS A N， et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial［J］. Eur Urol， 2019， 75（3）: 410-418.
7.SWIFT S L， LANG S H， WHITE H， et al. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review［J］. Future Oncol， 2019， 15（28）: 3283-3303.
8.JIANG W D， YUAN P C. Development and validation of prognostic nomograms for patients with metastatic prostate cancer［J］. Int Urol Nephrol， 2019， 51（10）: 1743-1753.
9.PAGLIARULO V. Androgen deprivation therapy for prostate cancer［J］. Adv Exp Med Biol， 2018， 1096（1）: 1-30.
10.OWEN P J， DALY R M， LIVINGSTON P M， et al. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update［J］. Prostate Cancer Prostatic Dis， 2017， 20（2）: 137-145.
11.FINKELSTEIN J S， LEE H， BURNETT-BOWIE S A， et al. Gonadal steroids and body composition， strength， and sexual function in men［J］. N Engl J Med， 2013， 369（12）: 1011-1022.
12.BRAND JS， van der TWEEL I， GROBBEE D E， et al. Testosterone， sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies［J］. Int J Epidemiol 2011， 40（1）: 189-207.
13.ZAMBONI M， MAZZALI G， FANTIN F，et al. Sarcopenic obesity: a new category of obesity in the elderly［J］. Nutr Metab Cardiovasc Dis， 2008， 18（5）: 388-395.
14.SMITH M R， LEE H， FALLON M， et al. Adipocytokines， obesity and insulin resistance during combined androgen blockade for prostate cancer［J］. Urology， 2008， 71（2）: 318-322.
15.WALL BA， GALVO D A， FATEHEE N， et al. Exercise improves V-O2max and body composition in ADT-treated prostate cancer patients［J］. Med Sci Sports Exerc， 2017， 49（8）: 1503-1510.
16.SWINBURN B A， CATERSON I， Seidell J C， et al. Diet， nutrition and the prevention of excess weight gain and obesity［J］. Public Health Nutr， 2004， 7（1A）: 123-146.
17.TZORTZIS V， SAMARINAS M， ZACHOS I， et al. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications［J］. Hormones， 2017， 16（2）: 115-123.
18.DOCKERY F， BULPITT C J， AGARWAL S， et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinemia［J］. Clin Sci （Lond）， 2003， 104（2）: 195-201.
19.KEATING N L， O MALLEY A J， SMITH M R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer［J］. J Clin Oncol， 2006， 24（27）: 4448-4456.
20.Nguyen P L， Alibhai S M， Basaria S，et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them［J］. Eur Urol， 2015， 67（5）: 825-836.
21.MACLEOD J， FRANZ M J， HANDU D， et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for type 1 and type 2 diabetes in adults: nutrition intervention evidence reviews and recommendations［J］. J Acad Nutr Diet， 2017， 117（10）: 1637-1658.
22.彭璐.糖尿病足病医学营养治疗指南［J］.中国组织工程研究， 2019， 23（35）: 5682-5689.
23.SHAHANI S， BRAGA-BASARIA M， BASARIA S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis［J］. JCEM， 2008， 93（6）: 2042-2049.
24.REZAEI M M， REZAEI M M， GHOREIFI A， et al. Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy［J］. Can Urol Assoc J， 2016， 10（9-10）: E300-E305.
25.BRAGA-BASARIA M， DOBS A S， MULLER D C， et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy［J］. J Clin Oncol， 2006， 24（24）: 3979-3983.
26.Prospective Study Collaboration， Lewington S， Whitlock G， et al， Blood cholesterol and vascular mortality by age， sex， and blood pressure: a metaanalysis of individual data from 61 prospective studies with 55，000 vascular deaths［J］. Lancet， 2007， 370（9602）: 1829-1839.
27.SMITH M R， FINKELSTEIN J S， MCGOVERN F J， et al. Change in body composition during androgen deprivation therapy for prostate cancer［J］. J Clin Endocrinol Metab， 2002， 87（2）: 599-603.
28.BENNETT G G， STEINBERG D， ASKEW S， et al. Effectiveness of an app and provider counseling for obesity treatment in primary care［J］. Am J Prev Med， 2018， 55（6）: 777-786.
29.MAGNO S， CECCARINI G， PELOSINI C， et al. LDL-cholesterol lowering effect of a new dietary supplement: an open label， controlled， randomized， cross-over clinical trial in patients with mild-to-moderate hypercholesterolemia［J］. Lipids Health Dis， 2018， 17（1）: 124.
30.SMITH M R， MALKOWICZ S B， CHU F， et al， Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study［J］. J Urol， 2008， 179（1）: 152-155.
31.RHEE H， GUNTER J H， HEATHCOTE P， et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management［J］. BJU Int， 2015， 115（Suppl 5）: 3-13.
32.SAMPER O T S P M， MUOZ GARCA J L， ROS KAVADOY Y， et al. SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre， cross-sectional study［J］. Rep Pract Oncol Radiother， 2015， 20（5）: 370-376.
33.MUNOZ GARCIA J， SAMPER OTS P， RIOS KAVADOY Y， et al. Cross-section observational study about prevalence of metabolic syndrome and osteoporosis in prostate cancer treated with androgen-deprivation therapy and their impact on quality of life （SIMBOSPROST）: Gicor Group［J］. Intl J Rad Onc Bio Phys， 2013， 87（Suppl）: 356.
34.TSAI H T， KEATING N L， STEPHEN K， et al. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer［J］. J Urol， 2015， 193（6）: 1956-1962.
35.SMITH J C， BENNETT S， EVANS L M， et al. The effects of induced hypogonadism on arterial stiffness， body composition， and metabolic parameters in males with prostate cancer［J］. J Clin Endocrinol Metab， 2001， 86（9）: 4261-4267.